荃信生物-B（02509）于2026年3月5日发布截至2026年2月28日的月度证券变动公告。公告显示，公司已发行股本总数保持227,071,600股不变，注册股本同样维持人民币227,071,600元。报告期内，公司普通股（H股）无新增发行，主要变动来源于股份购回。
根据公告，2026年2月末，公司已发行股份（不含库藏股）为224,567,600股，较上月底减少307,000股。同期库藏股从2,197,000股增加至2,504,000股，增幅为307,000股。购回价格区间约在每股20.12港元至20.24港元之间，上述购回股份目前被列为库存股份。
公告补充说明，当月并无关于股份期权、权证、可换股票据或其他协议安排的发行或变动信息。截至2月28日，公司股本总数仍维持在227,071,600股。其中，公司确认相关购回及持有库藏股份事宜均符合香港联交所《上市规则》和相关法律法规的要求，此次公告由公司董事会秘书和联席公司秘书胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.